Since Luna et al. recently reported that BTZ sensitizes cancer stem cells from multiple malignancies to allogeneic NK cells [26], we sought to examine whether BTZ could also sensitize patient-derived GBM cells to autologous NK cells and determine the mechanisms of effect. The gene discussed is CASC3; the disease is glioblastoma.